One of the unsung pillars of Roche/Genentech Inc.’s oncology strategy is the company’s in-house antibody engineering prowess, according to the global head of the cancer immunotherapy product development program.
“One of the most interesting differentiators we have” in the competitive oncology space is “our ability to get to next-generation...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)